En

ABOUT HOOMYA

關于宏雅



深圳市賽百諾中加基因技術有限公司是(shì)由臨床γ₩'藥理(lǐ)學家(jiā)、我國(guó)遺傳藥理(lǐ)學與藥物(wù)基因♦☆₩組學的(de)開(kāi)拓者和(hé)奠基人(r≤≈δ♥én)、個(gè)體(tǐ)化(huà)醫(yī)學的(de€¥λ)倡導者和(hé)引領者周宏灏院士及其團€•隊發起設立，緻力于個(gè)體(tǐ)化(huà)×β>醫(yī)學（精準醫(yī)學）檢測技(jì)Ω×術(shù)的(de)研究與産業(yè)化(hδ★σuà)的(de)高(gāo)科(kē)技(jì)公司。公司主要(yào)從(♣™‍&cóng)事(shì)個(gè)體(tǐ)化(huà)醫(₩₽yī)學檢測産品（含産品科(kē)研、CDMO、儀器(qì)與設β 備、試劑耗材及檢測服務）的(de)開(kāi)發、運營與市(shì)場(ch≠×₩ǎng)推廣，打造精準醫(yī)學時(shí)代±★‍✔的(de)專業(yè)個(gè)體(tǐ)化(h♠'uà)醫(yī)學檢測運營服務平台.

Hunan Hongya Gene Techn←∑ology Co., Ltd. was founded φ✘δby academician Zhou Hongha​§>®o, a clinical pharma♠♠σcologist, pioneer and founder of p£↕harmacogenetics and ε↕​pharmacogenomics in m≤♠' y country, and advocate and §ε​leader of personalized medicine, anα'≈d his team. It is a high-tech ✔¶company dedicated to the research an¶♦ ←d industrialization o☆∞♠✔f personalized medicineα₽  (precision medicine) testπαing technology. The company is m•↕ainly engaged in the₽‍ development, operation ★≤ and marketing of personalizγ≤ed medicine testing products (inc¶∞≈luding product research, CDMO, i₹↑♣&nstruments and equipment, reagent  s and consumables, an ±♦d testing services), creat≠↓ing a professional personalized"γ♥↑ medicine testing operat↕↕↑ion service platform in the era¶®β of precision medicine.





公司聯合以湘雅醫(yī)學檢驗所為(wèi¶₽↑)主體(tǐ)的(de)國(guó)內(nèi)外(wài)多(duō)家&σ(jiā)個(gè)體(tǐ)化(huà)✔δ醫(yī)學（精準醫(yī)學)專業(yè)研♦≈♦究機(jī)構，引進頂尖學者、 美(měi)國(guó©₩♦)墨菲特癌症中心醫(yī)學主任霍華德 · L · 麥克勞德為(wèi)代表的(de)專家(jiā)技(jì)術(shù)團隊，整合國(g∏←±uó)內(nèi)外(wài)先進的(de)個(gβ↓è)體(tǐ)化(huà)醫(yī)學檢$ ☆✔測技(jì)術(shù)平台， 以研發帶動生(shēn¶∑>≤g)産和(hé)銷售，依托具有(yǒu)先進性的(de)分(fēn)子(zǐ¶←§)診斷核心技(jì)術(shù)，在體(tǐ)¶ ★外(wài)診斷，尤其是(shì)高(gāo)端的(deπ↓​)分(fēn)子(zǐ)診斷領域形成了(le) 一₩ε'(yī)系列具有(yǒu)自(zì)主知(zh•↑ī)識産權的(de)産品。
    The co✔εmpany has joined forces wit₽↕h a number of Persona®±lized medicine (prec§δision medicine) professional r®±✘esearch institutes at home a→'nd abroad, mainly based onπ♥£σ the Xiangya medical labor★✔©atory, howard L. McCloud, med✘↓♥ical director of the Murphy Cancer→§​₹ Center in the United $←↕States and a leading λσscholar, was brought in to represenα&t the expert and technical teβγ am to integrate advanced Personalize©₽>​d medicine detection te÷׶chnology platforms at home and abr÷σ♣oad, a series of products with in↓δdependent intellectual‌™ property rights have ↕ been developed in the field of in vi₹&tro diagnosis, especially in high-end m¥¥‍olecular diagnosis.

公司目前主營業(yè)務包括各類應用(yòng)于無創産׶前篩查、疾病預測、疾病早期篩查、疾病早期分(fēn)子(zǐ)診↑'™λ斷與分(fēn) 子(zǐ)分(fēn)型、疾病個(gè)體(φ₽tǐ)化(huà)用(yòng)藥指導、疾©∞→♥病預後監測的(de)分(fēn)子(zǐ)檢測産品，已<≠↓‌形成覆蓋全國(guó)的(de)營銷網絡，ε‍成為(wèi)個(gè)體(tǐ)化(huà↔♥←) 醫(yī)學（精準醫(yī)學）專業(yè)服♣↑務領域的(de)優勢品牌企業(yè)。
    At pr•×πσesent, the company's main ♠♦‌λbusiness includes various applicat€Ωions in non-invasive≈$α≠ prenatal screening, disea↓₽₹✔se prediction, disease early screeni↕™☆ng, disease early mol₹∑∏ecular diagnosis and classificati♣® λon, the molecular detection products ofβ£↑ sub-typing, disease individualize€÷€d medication guidance and disease pr↔$λ₩ognosis monitoring have form™÷$ed a nationwide marketi↓σ♠‌ng network and become indivi↓¥dualized, medical (precision me≤✘dicine) professional servi& '★ces in the field of domina←​≈αnt brand enterprises

技(jì)術(shù)團隊Technical Team

公司聯合以湘雅醫(yī)學檢驗所為(wèi)主體♦γ≠(tǐ)的(de)國(guó)內(nèi)外(wài)多(duō)家(j"∞αiā)個(gè)體(tǐ)化(huà)醫(yī)學（精準醫<π(yī)學）專業(yè)研究機(jī)構，引進以 頂尖學者、美(β¶měi)國(guó)墨菲特癌症中心醫(yī)學主任霍華德 · L · 麥克勞德d為(wèi)代表的(de)專家(jiā)技(jì)術(shù)團 >∑隊，整合 國(guó)內(nèi)外(wài)先進的(de)個(‍₹€gè)體(tǐ)化(huà)醫(yī)學檢測技(↓>jì)術(shù)平台，以研發帶動生(shēng)←≥>"産和(hé)銷售，依托具有(yǒu)先進性的(de)分(fēn)子(zǐ×≤↑)診斷核心技(jì)術(shù)， 在體(tǐ)外(wà✔→i)診斷，尤其是(shì)高(gāo)端∞φ$∑的(de)分(fēn)子(zǐ)診斷領域形成了(le)一(yī)系列具有(yǒ♠•u)自(zì)主知(zhī)識産權的(de)産品。
The company has teamed up ↔ with a number of Personalize÷♦∞d medicine (precision •®£medicine) professional research ♥βinstitutes at home and abroa↑←↓¥d, mainly based on the Xiangya ¥÷‍ medical laboratory, howard L. M£≥β↓cCloud D, medical director of the Murph' y Cancer Center and a lead€≈ing scholar, is the represen±÷↔tative of the expert and techn≥≥ical team, which integratesγ∞€↕ the advanced Personalized medicin®≤e detection technology pl♠π∑atform at home and abroad, in vi©δ↓ tro diagnosis, especially in ‍§high-end molecular diagnosis field, ha​β↕♥s formed a series of prod§♦ucts with independent intellectua®↑≥€l property rights, relying on advanced σ"molecular diagnosis λ✔σcore technology.

主營業(yè)務Business

公司目前主營業(yè)務包括各類應用(yòng)于無創産前篩查、疾✔∑病預測、疾病早期篩查、疾病早期分(fēn)子(zǐ)診斷與₽γ≠分(fēn)子(zǐ) 分(fēn)型、疾病∞♦±個(gè)體(tǐ)化(huà)用(yòng)藥指導、疾病預後監測的(d★↔✘÷e)分(fēn)子(zǐ)檢測産品，業(yè)務 $版圖已遍布湖(hú)南(nán)、湖(hú)北(běi)、§±江蘇、浙 江、安徽、上(shàn★♦∑g)海(hǎi)、北(běi)京、天津、σ®河(hé)南(nán)、河(hé)北(běα πi)、山(shān)東(dōng)、山(shān)西(xī)、陝西(xīδ​")、遼甯、廣東(dōng)、廣西(xī)、雲南(nán)、 ♥♣¶π 貴州等地(dì)區(qū)。
At present, the comp®∑'any's main business incl♦∏udes various applicat×♦♥ions in non-invasive preασ§•natal screening, disease≠β∞ prediction, disease ear∑γly screening, disease eγ →arly molecular diagnosis and molecular,β∞< molecular testing produc  γts for typing, individualized medicat‍©ion guidance, and disease ​™&→prognosis monitoring, the business'₹& scope has spread over Hunan, Hubei, ↕ Jiangsu, Zhejiang, Anhui, ShΩ ₹anghai, Beijing, Tianjin, Henan, Hebei,​¶π Shandong, Shanxi, Shaanxi, Liaoning,& δφ Guangdong, Guangxi, Yun" >☆nan, Guizhou and other reg∑✘¥∏ions.

行(xíng)業(yè)領域Industry sector

個(gè)體(tǐ)化(huà)醫(y♦π©<ī)學Personalized Medicine 

個(gè)體(tǐ)化(huà)醫(±©€§yī)學是(shì)21世紀醫(yī)學發展的(de)必然趨勢。随著(zh±$≥εe)人(rén)類基因組計(jì)劃的(de)完成和(hé)後基因組學的(d÷ e)深入研究， 越來(lái)越多(duō)™↕≠的(de)緻病基因被定位，更多(duō)疾病發生(shēng)的☆↑(de)遺傳學基礎得(de)以闡明(míng)，與人(rén)類♦&₹↓生(shēng)理(lǐ)、病理(lǐ)以及藥物(wù)效應 <♠ 和(hé)毒副反應相(xiàng)關的(de)基因特征σ♥∏不(bù)斷被揭示，促使醫(yī)學模式由經典的(de)基于規律總☆​結的(de)“标準化(huà)醫(yī)學”，向基 于個( §‍εgè)體(tǐ)基因差異進行(xíng)的(de)“✘£₽≠量體(tǐ)裁衣”式的(de)“個(gè)體(tǐ)化(huà)醫(y÷α÷ī)學”轉變。個(gè)體(tǐ)化(huà)醫(yī)學是(shì)根據"↓β∑個(gè)體(tǐ)的(de)基因信息對(duì)疾病 進行<→(xíng)診斷、治療和(hé)風(fēng)險評估，使疾病的(d∞&‌e)診治更為(wèi)精确、高(gāo)效，顯著提升醫(yī)療質量™✔₹≥。個(gè)體(tǐ)化(huà)醫(yī)學目前發 "★展最為(wèi)成熟的(de)領域是(shì)個(gè)體(tǐ)化(huà←÷↕')用(yòng)藥，即以每個(gè)患者的(de)基®λ因信息為(wèi)基礎決定個(gè)人(rén)的(de)←' £藥物(wù)治療方案，從(cóng)基因 ¶↑ 組成或表達的(de)差異來(lái)預測£™ε疾病的(de)治療效果或毒副作(zuò)←€☆用(yòng)，對(duì)每個(gè)患者選♦δσ擇最适宜的(de)藥物(wù)療法進行(xíng)治療。 →€ 個(gè)體(tǐ)化(huà)醫(yī)學彌補了(le©±)循證醫(yī)學的(de)缺點，其治療更有(yφ§>↔ǒu)針對(duì)性，可(kě)以按照÷©±(zhào)個(gè)體(tǐ)對(duì)某種特定疾病易感÷≠↕性的(de)不(bù)同 或對(duì)某種特定治療γ♠ →反應性的(de)不(bù)同，把人(réΩ​שn)群分(fēn)為(wèi)不(bù)同的(de)亞群→$‌★，進而對(duì)患者進行(xíng)有(y☆✔ǒu)效地(dì)預防或治療性幹預， 節$÷α£約醫(yī)療費(fèi)用(yòng)和(hé)避免毒副反應 ‍Personalized medicine is an inevita↓Ω∏§ble trend in the developε♣‌ment of medicine in the 21st centur☆<y.With the completion of the h® ↓uman genome project and inδπ-depth research on post-ge↑β★↔nomics, more and more dise&¶‌ase-causing genes have been lεβocated, and the geneti≥≥♥c basis of more diseases has be↕₩±en elucidated, which is×♦←♣ related to human physiology, paΩ≤thology, drug effects and toxic sid≤↕®e effects. Gene characteristics ε'→≥are constantly being reve₹©♦λaled, prompting the medical mode δ™ l to change from the clasε✔↑₽sic "standardized medici$± ♣ne" based on rule summaries to "φ±tailor-made" "individualizπ→ε✘ed medicine" based on individual genet"✘ic differences.Personalized medi♥₩cine is the diagnosis, treatment↑‍ ♥ and risk assessment of di<¥✔♠seases based on individu±₽÷φal genetic information, making the dia×¥gnosis and treatment of diseases more ×₩πaccurate and efficient, and sigδπ>αnificantly improving the quality of me÷$€☆dical care.The most mature field of p∑Ωersonalized medicine is persoφ↕©εnalized medicine, which determinε εes individual drug treatment plans basφ§ed on each patient'。

個(gè)體(tǐ)化(huà)醫(yī)學檢測Personalized Medicine

通(tōng)過利用(yòng)專業(yè)檢測儀器(qì)平‍∞σ 台和(hé)配套的(de)試劑、耗材，檢測與疾病的♥®(de)發生(shēng)和(hé)用(yò"™✘≈ng)藥相(xiàng)關基因的(de)結構改變、表達 →βαε 和(hé)代謝(xiè)變化(hu>π♠à)等，進一(yī)步使用(yòng)數(shù)據庫、分(fēn)析模型、軟↑•≤件(jiàn)等工(gōng)具對(duì)‌←∏★檢測結果進行(xíng)專業(yè)分(fēn)析并對(duì)分(fēn)₹©π析結果進行(xíng)專業(yè) 咨詢（針對Ω¶(duì)受檢者及其醫(yī)生(shēng)），對(duì)疾δ¥病進行(xíng)個(gè)性化(huà)的(de)預©÷測、診斷、治療決策和(hé)檢測的(de♠≈<‌)臨床檢測服務。